FDA approves first US freeze-dried plasma for emergencies

A bleeding patient far from a hospital may be separated from plasma by a freezer, a thawing step and a long journey. The US Food and Drug Administration has now licensed Ezplaz Freeze Dried Plasma, the first freeze-dried plasma product in the country, for emergency use when other plasma products are unavailable.

The product tackles a practical storage problem. Conventional fresh frozen plasma preserves clotting proteins but requires frozen storage and thawing, conditions that are difficult to maintain in ambulances, disaster zones, rural communities and military settings. Ezplaz turns a single unit of fresh frozen plasma into a dry product that can be kept for 12 months at temperatures between 36 and 77 degrees Fahrenheit (2 to 25 degrees Celsius).

When a transfusion is needed, clinicians add sterile water supplied in the kit. The plasma reconstitutes in about 2.5 minutes. Each kit includes one unit of freeze-dried plasma, a 250-milliliter bag of sterile water, a fluid transfer set and a transfusion set; its flexible plastic bag also reduces the risk of breakage during transport. Ezplaz comes as group AB plasma and group A plasma with low levels of anti-B antibodies, selected to lower mismatch risk when a patient's blood type is unknown.

So what changes in practice? Emergency teams may have plasma available in places where frozen products cannot reach patients quickly enough. The license covers adults with bleeding, people undergoing massive transfusions and some patients taking warfarin who need urgent reversal. It does not make Ezplaz a universal replacement: the FDA says its benefit is logistical, and has not established improved survival compared with conventional plasma.

The evidence also leaves an important boundary around the result. An early safety study involved 24 healthy adults, a group that cannot fully predict performance in bleeding patients under real emergency conditions. Like other plasma products, Ezplaz carries risks including allergic reactions, transfusion-related lung injury, circulatory overload and incompatibility reactions; the FDA has also flagged thromboembolic events as an incompletely characterized risk and required a post-approval study to monitor it.